Functional Connectivity and Associated Neuropeptides Variations in Treatment Resistant Schizophrenia Patients: Treatment Efficacy of add-on Sodium Benzoate

Although antipsychotic is effective for schizophrenia, however, still certain proportion of patients were not responsive to treatment. Treatment resistant schizophrenia (TRS) is accompanied by function decline and heavy burden. In recent decades, the biological mechanism of schizophrenia extended from dopamine theory to the role of glutamate system. This shift could be an alternative pathway to developing the treatment of TRS. Sodium benzoate (SB) could be an option as a glutamatergic agent for the patients with TRS. However, most evidence of SB is for treating patients with schizophrenia and other mental disorders but the evidence for treating patients with TRS is scarce. To predict the treatment response of SB will be an urgent topic in the future. Little is known about the precise medicine for treating patients with TRS. The present project will extend our pilot randomized clinical trial on SB for TRS. A total of 90 patients with TRS will be enrolled from three centers and will be assigned to 8 weeks of treatment with SB or placebo (2:1). A comprehensive battery of potential markers will be employed, including 1H- magnetic resonance spectroscopy (MRS), brain functional connectivity, genotyping, immune biomarkers, cognitive function, and clinical characteristics. The efficacy of SB on TRS will be confirmed in this project. Predictors for treatment response will be identified. Artificial intelligence algorithms will be used for probing the feasibility of precision medicine.

Start Date10 Apr 2024

Sponsor / Collaborator

National Cheng Kung University Hospital

NCT05906303

/ Unknown statusPhase 1IIT

Caffeine in the Second Stage: A Randomized Control Trial in Low-risk Nulliparous Mothers at Term

Single blind, randomized control trial to determine benefit of caffeine and sodium benzoate on the second stage of labor

Start Date01 Dec 2023

Sponsor / Collaborator-

100 Clinical Results associated with Sodium Benzoate

100 Translational Medicine associated with Sodium Benzoate

100 Patents (Medical) associated with Sodium Benzoate

51,022

Literatures (Medical) associated with Sodium Benzoate

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

2,5-Dihydroxyphenylethanone: an anti-melanogenic bioactive compound isolated from Ganoderma cochlear

Article

Author: Ning, Meng ; Peng, Xing-Rong ; He, Min ; Liu, Xiao-Cui ; Qiu, Ming-Hua

2,5-dihydroxyacetophenone, a natural product from the fruiting bodies of Ganoderma cochlear, can effectively and safely inhibit the production of melanin in zebrafish model. To achieve analogues with more significant inhibition, 9 analogs were synthesised and 13 analogues were purchased commercially. Among them, 14 compounds can inhibit melanin production, of which 5 compounds displayed the most significant inhibitory effects, with inhibitory rates of more than 80%, compared to positive control SymWhite^®377 (phenylethyl resorcinol). This study elucidated the melanin-inhibitory effects of 2,5-dihydroxyacetophenone and its analogs, providing a theoretical foundation for their potential applications in anti-melanogenic reagents.

31 Dec 2025·CyTA-Journal of Food

Phytochemical composition, phytotoxicity, and ADME modeling of Artemisia absinthium L.: implications for food safety and pharmaceutical applications

Author: Benali, Mohammed ; Gharibi, Elkhadir ; Mothana, Ramzi A. ; Ed-darraz, Fatima-Zahrae ; Bouyanzer, Abdelhamid ; Farihi, Ayoub ; Hawwal, Mohammed F. ; Hbika, Asmae

Artemisia absinthium, an aromatic herb distinguished by its characteristic bitter flavor, has been used in a variety of culinary applications.This study investigates its metabolites through phytochem. methods.The primary minerals in Artemisia absinthium stems are potassium (41%) and calcium (38.3%), forming most of its mineral content.The ethanolic extract exhibited the highest phenolic compound content, with 37.6 ± 0.09 mg GAE/g DE.The primary volatile compound identified was β-thujone, comprising over 26.6% of the volatile content.Palmitic acid is the predominant fatty acid in the hexanic extract (18.7%), while linoleic acid is the main fatty acid in the Et acetate extract (42.4%).Twenty phenolic compounds were identified, with 8-methoxyflavone, (+)-catechin hydrate, and chlorogenic acid as major compounds in dichloromethane, Et acetate, and ethanol extracts, resp.ADME modeling indicating that 8-methoxyflavone, a major component in the dichloromethane extract, is a promising candidate for drug development targeting the central nervous system.

01 Nov 2025·FUEL

Ru8@NU-1000 as difunctional photocatalysts for visible-light-driven efficient CO2 reduction integrated with furfurylamine oxidation

Author: Li, Huafeng ; Bu, Kang ; Lu, Jingting ; Bai, Liqun ; Zhang, Jiayi ; Chen, Da ; Qu, Yanan

The CO₂ reduction coupled with organic oxidation driven by solar energy to valuable chem. fuels is considered a potent approach for tackling contemporary energy and environmental issues.However, it is difficult to design both a dual functional photocatalyst and constructed overall reaction systems simultaneously.In this work, NU-1000′s micropores (12 Å) and mesopores (34 Å) can effectively accommodate Ru₈ guest mols. (1 nm), so we employ a mature impregnation method by incorporating Ru₈ into the pores of NU-1000 constructed a difunctional Ru₈@NU-1000 photocatalyst and improve the efficiency of CO₂ reduction and furfurylamine oxidation with high selectivity.The yields of CO and N-Furfurylidenefurfurylamine (NF) are 2596 and 11408 μmol g^-1h^-1 resp., showing a significantly greater amount of production than known similar studies.This catalytic system demonstrates long-term recyclability and stability by consecutive cycles experiment combine with characterization methods.A range of photochem. and spectroscopic studies verified the proposed photocatalytic mechanism.The utilization of Ru₈@NU-1000 in CO₂-furfurylamine photoredox reaction provides an overall reaction strategy to obtain two meaningful products at the same time, and also improves energy conversion efficiency and solar energy utilization, thereby promoting the development of green energy.

News (Medical) associated with Sodium Benzoate

18 Mar 2025

·www.syneurx.com

The Study of Ω-NaBen, a Novel Crystalline Form of Sodium Benzoate, Has Been Published in CNS & Neurological Disorders - Drug Targets, Indicating Its Superior Physicochemical Properties, Central Nervous System Effects, and Antipsychotic Activities.

English 繁體中文 “Ω-NaBen exemplifies a novel molecular entity much improves the biophysicochemical properties of the sodium benzoate.” Dr. Guochuan Emil Tsai said. Los Angeles, California, March 18, 2025 A recent study by SyneuRx has revealed superior pharmaceutical properties of Ω(omega)-NaBen, a novel crystalline form of sodium benzoate (NaBen). Ω-NaBen is the last alphabet of Greek. Ω-NaBen reflects the ultimate supreme value of the Nostradamus compound he first discovered and purified in 1556. In the study, Ω-NaBen can therapeutically improve all three major symptom domains of schizophrenia model, including positive, negative, and cognitive symptoms. Ω-NaBen also shows enhanced aqueous solubility and therefore improves the bioavailability and antipsychotic effects. In addition, Ω-NaBen also has much better crystal-stability either by itself or combined clozapine. The findings of Ω-NaBen have been published in the peer-reviewed journal, CNS & Neurological Disorders – Drug Targets. NaBen can increases the synaptic D-serine level to enhance NMDA receptor-mediated neurotransmission and therapeutically improve the symptoms of schizophrenia and cognition and memory of dementia. Nevertheless, the therapeutic effect is not dose-efficient due to the low bioavailability, therefore requires large unrealistic dosages. To improve NaBen, SyneuRx have discovered all crystalline forms of NaBen. Among them, Ω-NaBen exhibits exceptional bioavailability and therapeutic effects in the preclinical study. A multi-center clinical study (ClinicalTrials.gov Identifier: NCT03094429) is currently ongoing for assessing the safety and efficacy of Ω-NaBen as an add-on therapy with clozapine in refractory schizophrenia. Once developed successfully, the combination of clozapine and Ω-NaBen, a novel and superior crystalline NaBen, can work as a therapy beyond the last line treatment of schizophrenia—clozapine therapy. Professor Dr. Guochuan Emil Tsai from UCLA, highlighted, “Ω-NaBen exemplifies an effective strategy for the patients with schizophrenia and taking the last line of treatment, clozapine; it extend the frontier of the treatment of schizophrenia.” Privacy PolicyTerms of Use Contact Mission Leadership Team Major Milestone Antiviral Platform NMDA Platform Pipeline SNA11 SNG12 SND12 Press Release Publication Media

Clinical Study

17 Mar 2025

·www.globenewswire.com

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipated in mid-25 - Completed an equity offering with net proceeds of $59.2 million; extending operational runway into 2027 NEW YORK and BERLIN, March 17, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced fourth quarter and full year 2024 financial results and recent corporate highlights. “We are beginning the year in a strong financial position, thanks to the recent capital raise, which extends our runway into 2027, beyond when we expect the topline data readouts from the Phase 2 clinical trials of our two core programs, VLS-01 and EMP-01, in Q1’26” stated Srinivas Rao, M.D., Ph.D., Chief Executive Officer and Co-founder of atai. “Our team is focused on executing these trials rigorously and efficiently to drive forward our mission to transform patient outcomes in mental health. We also look forward to several key milestones this year, notably Beckley Psytech’s BPL-003 Phase 2b topline results in patients with treatment-resistant depression as well as RL-007 in patients with cognitive impairment associated with schizophrenia, both expected mid-2025.” Recent Clinical Highlights and Upcoming MilestonesVLS-01: N,N-dimethyltryptamine (DMT) for treatment-resistant depression (TRD) VLS-01 is an investigational proprietary oral transmucosal film formulation of DMT applied to the buccal surface, designed to fit within the established two-hour interventional psychiatry treatment paradigm.Dosed the first patient in Elumina, a Phase 2, multicenter, double-blind, randomized, placebo-controlled trial to assess the safety and efficacy of repeated doses of VLS-01 in patients with TRD.Topline data from the Phase 2 Elumina trial of VLS-01 are anticipated in the first quarter of 2026. EMP-01: R-enantiomer of 3,4-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) EMP-01 is an oral formulation of R-MDMA that demonstrated a unique, dose-dependent subjective effect profile in a Phase 1 trial that was generally found to be more similar to classical psychedelics than to racemic MDMA.Initiated an exploratory Phase 2, randomized, double-blind, placebo-controlled clinical study to assess the safety, tolerability and efficacy of EMP-01 in adults with SAD.Topline data from the Phase 2 study of EMP-01 are anticipated in the first quarter of 2026. BPL-003: 5-Methoxy N,N-dimethyltryptamine (mebufotenin) benzoate for TRD and alcohol use disorder (AUD) (strategic investment in Beckley Psytech) BPL-003 is an intranasal transmucosal formulation of mebufotenin benzoate designed to fit within the established two-hour interventional psychiatry treatment paradigm.In March 2025, Beckley Psytech completed patient enrollment in the eight-week, double-blind, core stage of the global Phase 2b clinical trial of BPL-003 in 196 patients with TRD. Topline results from the core phase of the study are expected in mid-2025.In January 2025, Beckley Psytech announced positive topline data from its open-label Phase 2a study of BPL-003 in 12 patients with moderate-to-severe AUD. Initial data demonstrated that a single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months and was well-tolerated with no serious adverse events reported. RL-007: Pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia (CIAS) (strategic investment in Recognify Life Sciences) RL-007 is an orally bioavailable compound that has demonstrated pro-cognitive effects in multiple pre-clinical and clinical studies, including two Phase 1 and two Phase 2 trials.Recognify Life Sciences is running a Phase 2b proof-of-concept study in 234 patients living with CIAS. Topline results are expected in mid-2025. Consolidated Financial ResultsCash, cash equivalents, and short-term securities: As of December 31, 2024, the Company had cash, cash equivalents, restricted cash and short-term securities of $72.3 million compared to $154.2 million as of December 31, 2023. The decrease of $81.9 million was primarily driven by $82.4 million net cash used in operating activities, $15.0 million for the Beckley Psytech investment, and $7.7 million of additional investments to advance our programs; partially offset by $16.1 million in proceeds from the partial sale of our ADS holdings in Compass Pathways, and $5.0 million in proceeds from our committed term loan with Hercules Capital, Inc. In February 2025, the Company completed an equity offering with net proceeds of $59.2 million and now expects its cash, short-term securities, and public equity holdings to be sufficient to fund operations into 2027. Research and development (R&D) expenses: R&D expenses were $18.9 million and $55.5 million for the three and twelve months ended December 31, 2024, respectively, as compared to $14.2 million and $62.2 million for the comparable prior year periods. The year-over-year full-year decrease of $6.7 million was primarily attributable to a $5.5 million decrease in R&D personnel-related expenses and a $1.4 million decrease in program-specific expenses. The overall decrease in program-specific spend relates to the wind-down of certain programs, offset by the increase in on-going clinical trials and our non-hallucinogenic discovery program. The Company is anticipating R&D spend to increase as its R&D programs progress into later stage clinical trials. General and administrative (G&A) expenses: G&A expenses for the three and twelve months ended December 31, 2024 were $11.3 million and $47.5 million, respectively, as compared to $19.4 million and $63.6 million for the comparable prior year periods. The year-over-year full-year decrease of $16.0 million was primarily attributable to a $16.2 million decrease in personnel-related expenses and professional services. The Company expects the reduction in G&A spend over prior years to continue. Net income (loss): Net loss attributable to shareholders for the three and twelve months ended December 31, 2024 was $39.0 million and $149.3 million, respectively, as compared to $18.3 million and $40.2 million for the comparable prior year periods. Net loss attributable to shareholders for the twelve months ended December 31, 2024 includes $48.9 million of non-cash decrease in fair value of assets and liabilities, net and $25.5 million of non-cash share-based compensation. Net loss attributable to shareholders for the twelve months ended December 31, 2023 includes $86.6 million of non-cash increase in fair value of assets and liabilities, net, of which $69.0 million relates to a one-time accounting change, and $33.0 million of non-cash share-based compensation. About atai Life Sciencesatai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychology therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: our business strategy and plans; the potential, success, cost and timing of development of our product candidates, including the progress of preclinical and clinical trials and related milestones; expectations regarding our strategic investment in Beckley Psytech and other investments; expectations regarding our cash runway; and the plans and objectives of management for future operations, research and development and capital expenditures. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact InformationInvestor Contact:IR@atai.com Media Contact:PR@atai.com -- Financial Statements Attached -- ATAI LIFE SCIENCES N.V.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Amounts in thousands, except share and per share amounts) Three Months Ended Twelve Months Ended December 31, December 31, 2024 2023 2024 2023 (unaudited) License revenue $(5) $18 $308 $314 Operating expenses: Research and development 18,942 14,156 55,455 62,203 General and administrative 11,318 19,423 47,544 63,582 Total operating expenses 30,260 33,579 102,999 125,785 Loss from operations (30,265) (33,561) (102,691) (125,471)Other income (expense), net (8,919) 15,241 (45,714) 86,185 Net loss before income taxes (39,184) (18,320) (148,405) (39,286)Benefit from (provision for) income taxes 193 (428) 356 (1,016)Losses from investments in equity method investees, net of tax — (394) (2,000) (3,593)Net loss (38,991) (19,142) (150,049) (43,895) Net loss attributable to noncontrolling interests (33) (850) (780) (3,671)Net loss attributable to ATAI Life Sciences N.V. stockholders $(38,958) $(18,292) $(149,269) $(40,224)Net loss per share attributable to ATAI Life Sciences N.V. stockholders — basic and diluted $(0.24) $(0.12) $(0.93) $(0.25)Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders — basic and diluted 160,711,543 158,842,995 160,159,983 158,833,785 ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED BALANCE SHEET (Amounts in thousands) December 31, December 31, 2024 2023 Assets Cash and cash equivalents $17,505 $45,034 Securities carried at fair value 44,825 109,223 Short-term restricted cash for other investments 10,000 - Committed investment funds - 25,000 Prepaid expenses and other current assets 7,795 5,830 Short-term notes receivable - related party, net - 505 Property and equipment, net 2,535 981 Operating lease right-of-use assets, net 1,334 1,223 Other investments held at fair value 28,887 89,825 Other investments 42,079 1,838 Intangible assets, net 3,246 1,772 Goodwill 331 - Long-term notes receivable - related party, net - 97 Convertible notes receivable - related party - 11,202 Other assets 850 948 Total assets $159,387 $293,478 Liabilities and Stockholders' Equity Accounts payable $2,616 $4,589 Accrued liabilities 9,847 15,256 Current portion of lease liabilities 477 275 Short-term convertible promissory notes and derivative liability - related party 1,150 - Short-term convertible promissory notes and derivative liability 1,840 - Current portion of long-term debt 6,374 - Other current liabilities 2,647 - Contingent consideration liability - related party 110 620 Contingent consideration liabilities 212 1,637 Noncurrent portion of lease liabilities 732 990 Convertible promissory notes and derivative liability - related party - 164 Convertible promissory notes and derivative liability - 2,666 Long-term debt, net 14,133 15,047 Other liabilities 2,695 7,918 Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders 116,297 242,962 Noncontrolling interests 257 1,354 Total liabilities and stockholders' equity $159,387 $293,478

Phase 2Financial StatementClinical ResultPhase 1

23 Aug 2024

·pharma.economictimes.indiatimes.com

Govt bans 156 medicines including antibiotics, painkillers, multivitamins: Here is the full list

New Delhi: In a significant move aimed at safeguarding public health, the Indian government has banned 156 fixed-dose combination (FDC) drugs, including a variety of antibiotics, painkillers, multivitamins, and medications for treating fever and hypertension. This decision marks the largest crackdown on FDCs since 2016, when 344 such drugs were prohibited. The Union Ministry of Health and Family Welfare issued a gazette notification on Thursday, officially prohibiting the manufacture, sale, and distribution of the banned FDCs. The ban was based on the recommendations of an expert panel that reviewed a total of 324 FDCs. Impact on Pharmaceutical Industry The banned FDCs include popular combinations such as mefenamic acid and paracetamol injections, commonly used for pain relief and fever, and omeprazole magnesium with dicyclomine HCl, used to treat abdominal pain. The ban is expected to impact major pharmaceutical companies, including Sun Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, and Alkem Laboratories. Fixed Dose Combinations Drug Banned List Here is a table listing all 156 banned Fixed Dose Combinations (FDCs) SN Fixed Dose Combination (FDC) 1 Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain 2 Antimony Potassium Tartrate + Dried Ferrous Sulphate 3 Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride 4 Bismuth Ammonium Citrate + Papain 5 Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide 6 Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride 7 Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide 8 Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol 9 Mefenamic Acid + Paracetamol Injection 10 Omeprazole Magnesium + Dicyclomine HCl 11 S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L- Methylfolate + Choline bitartratee + Silymarin + L-ornithine Laspartate + Inositol + Taurine 12 Silymarin + Thiamine Mononitrate + Riboflavin + Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12 13 Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid 14 Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate 15 Sodium Citrate + Citric Acid Monohydrate Flavored with Cardamom Oil, Caraway Oil, Cinnamon Oil, Clove Oil, Ginger Oil + Alcohol 16 Sucralfate + Acelofenac 17 Sucralfate + Domperidone + Dimethicone 18 Sucralfate + Domperidone 19 Tincture Ipecacuanha + Tincture Urgenia + Camphorated Opium Tincture + Aromatic Spirit of Ammonia + Chloroform + Alcohol 20 Ursodeoxycholic Acid + Metformin HCl 21 Weak Ginger tincture + Aromatic Spirit of Ammonia + Peppermint Spirit + Chloroform + Sodium Bicarbonate + Compound Cardamom + Alcohol 22 Sucralfate + Pantoprazole Sodium + Zinc Gluconate + Light Magnesium Carbonate 23 Aloe + Vitamin E Soap 24 Povidone Iodine+ Metronidazole + Aloe 25 Azelaic acid + Tea Tree Oil + Salicylic acid + Allantoin + Zinc oxide + Aloe vera + Jojoba oil + Vitamin E + Soap noodles 26 Azithromycin + Adapalene 27 Calamine + Aloes + Allantoin 28 Calamine + Diphenhydramine Hydrochloride + Aloe + Glycerine + Camphor 29 Chlorphenesin + Zinc oxide + Starch 30 Clindamycin Phosphate + Zinc acetate 31 Gamma Benzene Hexachloride + Benzocaine 32 Glucosamine hydrochloride + Diacerein + Menthol + Camphor + Capsaicin 33 Hydroxyquinone 2.0%w/w + Octyl Methoxycinnamate 5.0% w/w + Oxybenzone 30 % w/w 34 Ketoconazole +Zinc Pyrithione +D-Panthenol +Tea Tree Oil +Aloes 35 Ketoconazole +Aloe vera+ Vitamin A Acetate 36 Ketoconazole +Aloes + ZPTO 37 Kojic Acid +Arbutin +Octinoxate +Vitamin E + Mulberry 38 Lornoxicam +capsaicin +menthol+ camphor 39 Lornoxicam + Thiocolchicoside +Oleum Lini +Menthol + Methyl salicylate 40 Menthol + Aloe vera Topical Spray 41 Menthol +Lignocaine HCl +Aloe vera gel +Clotrimazole +Diphenhydramine 42 Miconazole nitrate + Gentamicin + Fluocinolone Acetonide +Zinc Sulphate 43 Miconazole +Tinidazole 44 Minoxidil +Aminexil+ Alcohol 45 Minoxidil +Azelaic acid + saw palmetto 46 Minoxidil +Aminexil 47 Pine Bark extract+ Kojic acid +Sodium Ascorbyl Phosphate 48 Povidone Iodine +Tinidazole +Zinc sulphate 49 Povidone Iodine + Ornidazole + Dexpanthenol 50 Salicyclic acid +Aloe vera+ Allantoin +D-Panthenol 51 Silver sulphadiazine +Chlorhexidine Gluconate solution +Allantoin + Aloe vera gel +Vitamin E acetate 52 Sodium salicylate + Zinc gluconate + Pyridoxine HCl 53 Tetracycline + Colistin Sulphate 54 Clomiphene +Ubidecarenone 55 Combikit of Clomiphene Citrate + Estradiol Valerate 56 Flavoxate HCl +Ofloxacin 57 Clomiphene Citrate +N-Acetylcysteine 58 Primerose Oil +Cod liver oil 59 Sildenafil Citrate +Papaverine +L-Arginine 60 Tranexamic acid +Mefenamic acid + Vitamin K1 61 Divalproex Sodium +Oxcarbazepine 62 Divalproex Sodium + Levetiracitam 63 Ergotamine tartrate +Caffeine + Paracetamol +Prochlorperazine maleate 64 Piracetam + Ginkgo biloba extracts + Vinpocetin 65 Ginkgo biloba + methylcobalamin 66 Ginkgo biloba + methylcobalamin + Alpha lipoic acid +Pyridoxine HCl 67 Ginseng Extract +Dried extract of Ginkgo Biloba 68 Meclizine HCl+ Paracetamol + Caffeine 69 Nicergoline + Vinpocetine 70 Gamma Linolenic Acid + Methylcobalamin 71 Beclomethasone Dipropionate + Neomycin Sulphate + Clotrimazole + Lignocaine HCl 72 Boric acid+ Phenylephrine HCl + Naphazoline Nitrate + Menthol + Camphor 73 Naphazoline HCl + Chlorpheniramine Maleate + Zinc Sulphate + Hydroxy Propyl Methyl Cellulose 74 Chlorpheniramine Maleate + Naphazoline HCl + Zinc Sulphate + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 75 Chlorpheniramine Maleate + Naphazoline HCl + Hydroxy Propyl Methyl Cellulose 76 Chlorpheniramine Maleate + Sodium Chloride + Boric Acid + Tetrahydrozoline HCl 77 Chlorpheniramine Maleate + Phenylephrine HCl + Antipyrine 78 Ketorolac Tromethamine + Chlorpheniramine Maleate + Phenylephrine HCl + Hydroxy Propyl Methyl Cellulose 79 Ketorolac Tromethamine + Flurometholone 80 Naphazoline HCl + Zinc Sulphate + Boric Acid + Sodium Chloride+ Chlorpheniramine Maleate 81 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Boric Acid + Borax + Menthol + Camphor 82 Naphazoline HCl + Hydroxy Propyl Methyl Cellulose + Chlorpheniramine Maleate SN Fixed Dose Combination (FDC) 83 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Menthol + Camphor 84 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Hydroxy Propyl Methyl Cellulose 85 Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride + Sodium Chloride + Methylparaben 86 Methenamine + Sodium Benzoate + Benzyl Alcohol 87 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 88 Paracetamol + Phenylephrine Hydrochloride + Chlorpheniramine Maleate + Caffeine 89 Propoxyphene + Chlorpheniramine Maleate 90 Propoxyphene + Phenylephrine Hydrochloride + Chlorpheniramine Maleate 91 Propoxyphene + Diphenhydramine Hydrochloride + Phenylephrine Hydrochloride 92 Sodium Benzoate + Sodium Citrate + Citric Acid 93 Vitamin A Palmitate + Vitamin C + Vitamin E + Vitamin B6 + Vitamin B12 94 Vitamin A Palmitate + Vitamin C + Vitamin E + Niacinamide 95 Vitamin B6 + Vitamin B12 + Vitamin C 96 Vitamin B6 + Vitamin B12 + Niacinamide 97 Vitamin B12 + Vitamin B6 + Vitamin C + Folic Acid 98 Vitamin B12 + Vitamin B6 + Niacinamide + Folic Acid 99 Vitamin C + Vitamin E + Vitamin A + Niacinamide 100 Vitamin D + Calcium + Magnesium 101 Vitamin D + Calcium + Magnesium + Zinc 102 Calcium + Vitamin D + Vitamin K 103 Calcium + Vitamin D + Magnesium + Zinc 104 Calcium + Vitamin D + Vitamin K + Magnesium 105 Calcium + Vitamin D + Vitamin K + Magnesium + Zinc 106 Vitamin E + Vitamin A + Vitamin C + Niacinamide 107 Vitamin E + Vitamin A + Vitamin C + Folic Acid 108 Vitamin E + Vitamin A + Vitamin C + Biotin 109 Vitamin E + Vitamin A + Vitamin C + Vitamin B12 110 Vitamin E + Vitamin C + Folic Acid 111 Vitamin E + Vitamin C + Biotin 112 Vitamin E + Vitamin C + Vitamin B12 113 Vitamin E + Vitamin C + Zinc 114 Calcium + Vitamin D + Omega-3 Fatty Acids 115 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K 116 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Magnesium 117 Calcium + Vitamin D + Omega-3 Fatty Acids + Vitamin K + Zinc 118 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene 119 Vitamin A + Vitamin C + Vitamin E + Beta-Carotene + Zinc 120 Vitamin C + Vitamin E + Beta-Carotene 121 Vitamin C + Vitamin E + Beta-Carotene + Zinc 122 Vitamin C + Vitamin E + Selenium 123 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids 124 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Magnesium 125 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Zinc 126 Vitamin D + Calcium + Vitamin K + Omega-3 Fatty Acids + Biotin 127 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 128 Vitamin E + Vitamin A + Vitamin C + Zinc 129 Vitamin E + Vitamin A + Vitamin C + Selenium 130 Vitamin E + Vitamin A + Vitamin C + Biotin 131 Vitamin E + Vitamin A + Vitamin C + Folic Acid + Niacinamide 132 Vitamin E + Vitamin C + Beta-Carotene + Zinc 133 Vitamin C + Vitamin E + Biotin + Folic Acid 134 Vitamin C + Vitamin E + Beta-Carotene + Folic Acid 135 Vitamin C + Vitamin E + Beta-Carotene + Selenium 136 Vitamin E + Vitamin C + Beta-Carotene + Biotin 137 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Biotin 138 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Selenium 139 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B12 140 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Vitamin B6 141 Vitamin D + Calcium + Omega-3 Fatty Acids + Vitamin K + Folate 142 Calcium + Vitamin D + Magnesium + Vitamin K + Omega-3 Fatty Acids 143 Calcium + Vitamin D + Magnesium + Vitamin K + Biotin 144 Calcium + Vitamin D + Magnesium + Vitamin K + Selenium 145 Calcium + Vitamin D + Magnesium + Vitamin K + Vitamin B12 146 Calcium + Vitamin D + Magnesium + Vitamin K + Folate 147 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B6 148 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Vitamin B12 149 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Folic Acid 150 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Biotin 151 Calcium + Vitamin D + Vitamin K + Omega-3 Fatty Acids + Selenium 152 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids 153 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Zinc 154 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Biotin 155 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Selenium 156 Vitamin A + Vitamin C + Vitamin E + Omega-3 Fatty Acids + Vitamin B12

Drug Approval

100 Deals associated with Sodium Benzoate

External Link

KEGG	Wiki	ATC	Drug Bank
D02277	Sodium Benzoate	A16AX11	DBSALT001289

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	-	-	-
Hyperammonemia	-	-	-
Mycoses	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Schizophrenia, Treatment-Resistant	Phase 3	United States	SyneuRx International (Taiwan) Corp.	29 Mar 2017
Schizophrenia	Phase 3	Taiwan Province	SyneuRx International (Taiwan) Corp.	01 Jun 2014
Dementia	Phase 3	United States	SyneuRx International (Taiwan) Corp.	-
Alzheimer Disease	Phase 2	Taiwan Province	Formosa Biomedical Technology Corp.	08 Aug 2022
Autism Spectrum Disorder	Preclinical	China	Nanjing Medical University	25 Aug 2025
Citrullinemia	Discovery	Australia	Orpharma Pty Ltd.	06 Dec 2016
N-Acetyl Glutamate Synthetase Deficiency	Discovery	Australia	Orpharma Pty Ltd.	06 Dec 2016
Ornithine Carbamoyltransferase Deficiency Disease	Discovery	Australia	Orpharma Pty Ltd.	06 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03510741 (Pubmed \| Schizophr Bull Open)	Phase 2	Schizophrenia Add-on oxidative stress pathways \| NMDA neurotransmission	68	Sodium Benzoate	mwcsorojzz(xfliazbxqh) = dzfsbmxeiy hyhiukmhzd (hrhlzhceuv ) View more	Negative	01 Jan 2024
				N-acetylcysteine	mwcsorojzz(xfliazbxqh) = gmuxsbevsx hyhiukmhzd (hrhlzhceuv ) View more
CTRI/2017/08/009329 (Pubmed \| J Pediatr Gastroenterol Nutr)	Not Applicable	Chronic liver disease	86	Sodium Benzoate	mfdxbhtkxg(traphtwogv) = Sodium benzoate caused an increasing trend of adverse events with no effect on short-term survival kfzlfvdlqw (autgistwhg )	-	01 Feb 2020
				Placebo
NCT02111200 (BPA/Benzoate, CTgov)	Not Applicable	Urea Cycle Disorders, Inborn	7	Sodium Benzoate (Sodium Benzoate Arm)	gmzsctapcp(cjxjamhhzu) = tlcchahlld wmrehtcgsn (gxdfbogmbw, 3.1) View more	-	08 Dec 2017
				Sodium Phenylbutyrate (Sodium Phenylbutyrate Arm)	gmzsctapcp(cjxjamhhzu) = dfachepilt wmrehtcgsn (gxdfbogmbw, 0) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sodium Benzoate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation